Design Therapeutics (DSGN)
NASDAQ:DSGN
Want to see DSGN full AI Analyst Report?
DSGN Stock Chart & Stats
$8.94
-$0.66(-11.15%)
At close: 4:00 PM EST
$8.94
-$0.66(-11.15%)
Day’s Range― - ―
52-Week Range$3.33 - $17.25
Previous CloseN/A
Volume97.34K
Average Volume (3M)213.56K
Market Cap
$685.15M
Enterprise Value$644.51M
Total Cash (Recent Filing)$222.82M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding62,456,974
10 Day Avg. Volume267,018
30 Day Avg. Volume213,565
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.86
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$20.75Price Target Upside132.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMinimal leverage and substantial asset base provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing. This reduces near-term solvency risk, supports discretionary R&D pacing, and strengthens negotiating position for partnerships or licensing over the next 2–6 months.
Clinical Progress And Registrational PathDose-dependent biomarker increases and clinically meaningful functional gains in the DT-216P2 Phase 1/2 trial, with acceptable tolerability, materially de-risk the program. Management's plan to pursue a registrational path signals a shift toward definitive trials, improving the long-term prospect of approval if findings replicate.
Pipeline Breadth & Governance ExpertiseMultiple programs across distinct indications diversify clinical and commercial risk, offering several potential value inflection points. The board addition of an experienced drug developer enhances clinical and regulatory strategy, improving trial design and execution prospects over the medium term.
Bears Say
Pre-Revenue With Persistent LossesOperating without product revenue leaves the business fully dependent on R&D progress to create value. Persistent multi-year losses erode equity and increase the likelihood of future financings, making the investment thesis contingent on successful clinical outcomes rather than steady cash generation.
Negative Free Cash Flow And Accelerating BurnSustained negative free cash flow of this magnitude accelerates depletion of liquid assets and constrains the firm's ability to expand trials or progress multiple programs in parallel. Continued high burn raises the risk that milestone timelines will be impacted if additional capital is delayed.
Reliance On External Equity FinancingDependence on equity raises creates structural dilution risk and ties funding capacity to capital market conditions. If markets turn unfavourable or clinical readouts are delayed, financing terms may worsen, constraining strategic flexibility and potentially forcing program prioritization or slower development.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $3.33 and its highest was $17.25 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $685.15M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 56 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Apr 28, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.328 by $0.038.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 62,456,974 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.328. Following the earnings report the stock price went up 23.263%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Design Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.75 (132.10% Upside)
$20.75 (132.10% Upside)
Blogger Sentiment
Bullish
DSGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.65%
12-Months-Change
Fundamentals
Return on Equity
-33.07%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
DSGN Company Deck
DSGN Earnings Call
Q1 2026
0:00 / 0:00
DSGN Stock 12 Month Forecast
Average Price Target
$20.75
▲(132.10% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
16.86% Insiders
5.98% Mutual Funds
37.34% Other Institutional Investors
33.80% Public Companies and
Individual Investors